In this respect, Wei et al. designed enzyme-catalyzed responsive nanoparticles LOXL2-DDR1@MLP for pancreatic ductal adenocarcinoma (PDAC), which can release inhibitors of LOXL2 and discoidin domain receptor 1 (DDR1) in the tumor stromal to reduce the collagen crosslinking and remodel stroma topology. This evidence concerns the gene DDR1 and pancreatic ductal adenocarcinoma.